Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Sci Transl Med. 2012 Oct 10;4(155):155cm11. doi: 10.1126/scitranslmed.3003142.
Drug discovery is at a near standstill for treating psychiatric disorders such as schizophrenia, bipolar disorder, depression, and common forms of autism. Despite high prevalence and unmet medical need, major pharmaceutical companies are deemphasizing or exiting psychiatry, thus removing significant capacity from efforts to discover new medicines. In this Commentary, I develop a view of what has gone wrong scientifically and ask what can be done to address this parlous situation.
药物研发在治疗精神疾病方面陷入僵局，例如精神分裂症、双相情感障碍、抑郁症和常见形式的自闭症。尽管患病率高且未满足医疗需求，但大型制药公司正在淡化或退出精神病学领域，从而降低了发现新药的努力的重大能力。在这篇评论中，我提出了一种观点，即科学上出了什么问题，并探讨了可以采取什么措施来解决这种危险的情况。
